722 related articles for article (PubMed ID: 24299176)
21. Biocatalytic synthesis of intermediates for the synthesis of chiral drug substances.
Patel RN
Curr Opin Biotechnol; 2001 Dec; 12(6):587-604. PubMed ID: 11849941
[TBL] [Abstract][Full Text] [Related]
22. Selective synthesis of poly-substituted fluorine-containing pyridines and dihydropyrimidines via cascade C-F bond cleavage protocol.
Chen Z; Zhu J; Xie H; Li S; Wu Y; Gong Y
Org Biomol Chem; 2011 Aug; 9(16):5682-91. PubMed ID: 21717032
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, hypoglycaemic, hypolipidemic and PPARγ agonist activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones.
Khazi MI; Belavagi NS; Kim KR; Gong YD; Khazi IA
Chem Biol Drug Des; 2013 Aug; 82(2):147-55. PubMed ID: 23581650
[TBL] [Abstract][Full Text] [Related]
24. Annual review of new drugs--1973.
De Haen P
N Y State J Med; 1973 May; 73(10):1201-5. PubMed ID: 4572539
[No Abstract] [Full Text] [Related]
25. Evolva breeds small molecule drugs au naturel.
Wolfson W
Chem Biol; 2009 Jun; 16(6):577-8. PubMed ID: 19549594
[No Abstract] [Full Text] [Related]
26. Synthesis and chemistry of fluorine containing bioactive 1,2,4-triazines--an overview. Chemistry of uncondensed 1,2,4-triazines, Part III.
Abdel-Rahman RM
Pharmazie; 1999 Nov; 54(11):791-803. PubMed ID: 10603605
[TBL] [Abstract][Full Text] [Related]
27. Chemical constituents and biological activities of plants from the genus Ligustrum.
Gao BB; She GM; She DM
Chem Biodivers; 2013 Jan; 10(1):96-128. PubMed ID: 23341211
[No Abstract] [Full Text] [Related]
28. Fluorine in medicinal chemistry.
Böhm HJ; Banner D; Bendels S; Kansy M; Kuhn B; Müller K; Obst-Sander U; Stahl M
Chembiochem; 2004 May; 5(5):637-43. PubMed ID: 15122635
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of 2'-α-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase.
Parrish JP; Lee SK; Boojamra CG; Hui H; Babusis D; Brown B; Shih IH; Feng JY; Ray AS; Mackman RL
Bioorg Med Chem Lett; 2013 Jun; 23(11):3354-7. PubMed ID: 23639543
[TBL] [Abstract][Full Text] [Related]
30. Chemical structure does not define obviousness.
Harrison C
Nat Rev Drug Discov; 2012 Jun; 11(6):432-3. PubMed ID: 22653206
[No Abstract] [Full Text] [Related]
31. By any other name: ambiguity in marketing proprietary anti-infective agents.
Berger SA
Clin Infect Dis; 2007 Jan; 44(1):65-8. PubMed ID: 17143817
[TBL] [Abstract][Full Text] [Related]
32. [Is openness in the drug market possible?].
Dölle W; Schwabe U
Internist (Berl); 1986 Jan; 27(1):21-31. PubMed ID: 3514513
[No Abstract] [Full Text] [Related]
33. Practical synthesis of fluorine-containing α- and β-amino acids: recipes from Kiev, Ukraine.
Kukhar VP; Sorochinsky AE; Soloshonok VA
Future Med Chem; 2009 Aug; 1(5):793-819. PubMed ID: 21426081
[TBL] [Abstract][Full Text] [Related]
34. Theoretical studies of the reduction reaction of the anti-tumor drug FR900482.
Sapse AM; Jain DC
J Mol Model; 2007 Jan; 13(1):229-32. PubMed ID: 17024411
[TBL] [Abstract][Full Text] [Related]
35. New drugs and drug products approved in 1997.
Gage TW
Tex Dent J; 1998 Sep; 115(9):51-60. PubMed ID: 9807157
[No Abstract] [Full Text] [Related]
36. Complexes of the minor groove of DNA.
Geierstanger BH; Wemmer DE
Annu Rev Biophys Biomol Struct; 1995; 24():463-93. PubMed ID: 7663124
[TBL] [Abstract][Full Text] [Related]
37. Adopting orphan drugs: Congress tries to encourage new remedies for rare diseases.
Wallis C
Time; 1982 Oct; 120(15):76, 79. PubMed ID: 10317248
[No Abstract] [Full Text] [Related]
38. Large-scale oxidations in the pharmaceutical industry.
Caron S; Dugger RW; Ruggeri SG; Ragan JA; Ripin DH
Chem Rev; 2006 Jul; 106(7):2943-89. PubMed ID: 16836305
[No Abstract] [Full Text] [Related]
39. A tough market.
Ridley-Smith RM
N Z Med J; 2007 Aug; 120(1260):U2699. PubMed ID: 17726506
[No Abstract] [Full Text] [Related]
40. Fluorinated nucleosides.
Pankiewicz KW
Carbohydr Res; 2000 Jul; 327(1-2):87-105. PubMed ID: 10968677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]